Clopidogrel-Mediated P2Y

This prospective ex vivo and in vitro pharmacodynamic (PD)/pharmacokinetic investigation was conducted in patients with diabetes mellitus with (n = 31) and without chronic kidney disease (n = 30). PD assessments included platelet reactivity index, maximum platelet aggregation, and P2Y

Informations de copyright

© 2024 The Authors.

Déclaration de conflit d'intérêts

This study was funded by an investigator-initiated grant from the University of Florida and the Scott R. MacKenzie Foundation. The Scott R. MacKenzie Foundation had no role in the study design conception, conduct of the study, or decision to publish these results. Work by Drs Cavallari, Angiolillo, and Franchi is supported by the National Institutes of Health National Heart, Lung, and Blood Institute (1R01HL149752). Dr Franchi has received payment as an individual for consulting fee or honoraria from AstraZeneca, Bayer and Sanofi; and institutional payments for grants from PLx Pharma and The Scott R. MacKenzie Foundation. Dr Galli has received consulting fees or honoraria from Terumo, outside the present work. Dr Cavallari has received research support from Accriva Diagnostics. Dr Angiolillo has received consulting fees or honoraria from Abbott, Amgen, AstraZeneca, Bayer, Biosensors, Boehringer Ingelheim, Bristol-Myers Squibb, Chiesi, CSL Behring, Daiichi-Sankyo, Eli Lilly, Faraday, Haemonetics, Janssen, Merck, Novartis, PhaseBio, PLx Pharma, Pfizer, Sanofi, and Vectura; h and his institution has received research grants from Amgen, AstraZeneca, Bayer, Biosensors, CeloNova, CSL Behring, Daiichi-Sankyo, Eisai, Eli Lilly, Faraday, Gilead, Idorsia, Janssen, Matsutani Chemical Industry Co. Merck, Novartis, and the Scott R. MacKenzie Foundation. Dr Jakubowski was an employee of Eli Lilly and Company at the time of the studies. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.